cpeb4 Antibody

What is CPEB4 and what are its primary biological functions?

CPEB4 is a sequence-specific RNA-binding protein that binds to the cytoplasmic polyadenylation element (CPE), an uridine-rich sequence element (consensus sequence 5'-UUUUUAU-3') within the mRNA 3'-UTR. RNA binding results in a conformational change analogous to the Venus fly trap mechanism. CPEB4 regulates the unfolded protein response (UPR) in liver cells under ER stress conditions by maintaining translation of CPE-regulated mRNAs when global protein synthesis is inhibited. It is also required for cell cycle progression, specifically for cytokinesis and chromosomal segregation. In cancer biology, CPEB4 can function as an oncogene by promoting tumor growth and progression through positive regulation of t-plasminogen activator/PLAT translation .

How should I select the appropriate CPEB4 antibody for my research application?

Selection should be based on validated reactivity with your species of interest, application compatibility, and specificity. According to available data, when selecting a CPEB4 antibody, researchers should consider:

What are the critical parameters for storing and handling CPEB4 antibodies?

Most CPEB4 antibodies require specific storage conditions to maintain activity. Typically, storage at 2-8°C is recommended for sealed kits. Once opened, specific components may have different storage requirements. It's generally advised not to aliquot the antibody to prevent loss of activity through freeze-thaw cycles and protein denaturation . Always check manufacturer-specific guidelines, as storage requirements may vary between suppliers. For optimal results, minimize repeated freeze-thaw cycles and keep antibodies in recommended buffer conditions to prevent degradation that could affect experimental outcomes .

What is the optimal protocol for detecting CPEB4 using Western blotting?

For Western blot detection of CPEB4, a systematic approach is required:

• Sample preparation: Extract total protein from tissues or cells using standard lysis buffers containing protease inhibitors.

• Protein loading: Load 20 μg of protein per lane based on successful detection in published studies.

• Gel selection: Use SDS-PAGE gels appropriate for 80-90 kDa proteins (CPEB4's observed molecular weight).

• Transfer conditions: Transfer to PVDF membrane using standard protocols.

• Blocking: Block in 5% milk to reduce non-specific binding.

• Primary antibody: Dilute CPEB4 antibody 1:1000 and incubate overnight at 4°C.

• Detection method: Use appropriate secondary antibodies (Goat anti-Rabbit IgG H&L) and visualize using enhanced chemiluminescence reagents.

When interpreting results, expect to observe CPEB4 at approximately 80-90 kDa. Controls should include both positive cell lines (e.g., SGC7901, which shows high CPEB4 expression) and negative/low expression cell lines (e.g., AGS or GES-1 cells) .

How can I optimize CPEB4 detection in immunohistochemistry applications?

For optimal CPEB4 detection in immunohistochemistry:

• Tissue preparation: Use 4% PFA-fixed tissues with 0.2% Triton X-100 permeabilization for frozen sections.

• Antibody dilution: Start with 1:100 dilution (approximately 5.16 μg/ml) based on successful published protocols.

• Detection system: Use fluorescent secondary antibodies such as Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1:1000 dilution.

• Scoring system: Implement the immunoreactive score (IRS) system for quantification:

  • Staining intensity: 0=negative, 1=weak, 2=moderate, 3=strong

  • Percentage of positive cells: 0=0%–5%, 1=6%–25%, 2=26%–50%, 3=>50%

  • Calculate IRS by summing these scores (range 0-6)

  • Samples with IRS≥3 are considered positive, while IRS<3 is regarded as negative .

What are the common technical challenges when using CPEB4 antibodies and how can they be overcome?

Common challenges include:

• Non-specific binding: Observed as multiple bands in Western blot or background staining in IHC.

  • Solution: Increase blocking time/concentration, optimize antibody dilution, and include additional washing steps.

• Poor signal strength: Particularly problematic in tissues with low CPEB4 expression.

  • Solution: Consider signal amplification methods such as tyramide signal amplification for IHC or more sensitive ECL substrates for Western blot.

• Inconsistent results between applications: An antibody working well for Western blot may not perform optimally for IHC.

  • Solution: Select application-specific validated antibodies and optimize protocols for each technique independently.

• Cross-reactivity issues: May occur due to conserved domains across CPEB family proteins.

  • Solution: Use knockout-validated antibodies as demonstrated in the literature, where CPEB4 knockout A549 cell lysates showed absence of bands compared to wild-type .

How does CPEB4 expression correlate with cancer progression and metastasis?

Research indicates that CPEB4 plays a significant role in cancer biology, particularly in gastric cancer:

• Expression patterns: CPEB4 is overexpressed in gastric cancer tissues compared to matched normal tissues.

• Clinical correlations: High CPEB4 expression significantly associates with:

  • Clinical metastasis

  • Unfavorable prognosis in gastric cancer patients

• Functional significance: Experimental manipulation of CPEB4 levels has demonstrated that:

  • CPEB4 silencing inhibits cancer cell proliferation, invasion, and metastasis both in vitro and in vivo

  • CPEB4 overexpression promotes these malignant behaviors

• Mechanistic pathway: CPEB4 exerts its effects through ZEB1-mediated epithelial-mesenchymal transition (EMT), a critical process in cancer progression:

  • CPEB4 knockdown decreases ZEB1 expression

  • This suppresses EMT processes

  • Results in reduced cellular migration and invasion capabilities

What experimental models are most appropriate for studying CPEB4 function?

Based on published research, these experimental models have proven valuable for CPEB4 studies:

• Cell line models:

  • SGC7901 cells: Show high CPEB4 expression, useful for knockdown studies

  • AGS cells: Exhibit low CPEB4 expression, appropriate for overexpression studies

  • Additional validated cell lines include BGC823, MGC803, and MKN45 for gastric cancer research

• In vitro functional assays:

  • Cell proliferation: CCK-8 assay, colony formation assay, EdU incorporation assay

  • Migration: Wound healing assay, transwell migration assay

  • Invasion: Transwell invasion assay with Matrigel coating

• In vivo models:

  • Subcutaneous xenograft tumor models in nude mice for growth assessment

  • Lung metastasis models for evaluating metastatic potential

• Molecular manipulation approaches:

  • shRNA lentivirus vectors for stable CPEB4 knockdown

  • CPEB4 expression vectors for overexpression studies

  • Validation of manipulation via Western blot and immunofluorescence staining

How should I design experiments to investigate CPEB4's role in specific cellular processes?

For rigorous investigation of CPEB4 function, design experiments that include:

• Expression profiling:

  • Compare CPEB4 levels across normal and disease tissues/cells

  • Use both Western blot and immunohistochemistry for comprehensive assessment

• Gain and loss of function studies:

  • Implement both knockdown (shRNA) and overexpression approaches

  • Include appropriate controls (sh-NC for knockdown, empty vector for overexpression)

• Functional readouts:

  • Proliferation assessment: Combine multiple assays (CCK-8, colony formation, EdU)

  • Migration/invasion: Use both 2D (wound healing) and 3D (transwell) assays

  • In vivo validation: Measure tumor volume, weight, and metastatic nodules

• Molecular mechanism investigations:

  • Assess downstream targets (like ZEB1)

  • Analyze pathway components (EMT markers: E-cadherin, N-cadherin, Vimentin)

  • Confirm relationships through rescue experiments

• Translational relevance:

  • Correlate experimental findings with clinical parameters

  • Create IHC scoring systems for patient sample analysis

How can CPEB4 antibodies be employed in multiplexed detection systems?

For advanced multiplexing with CPEB4 antibodies:

• Co-staining protocols:

  • Select antibodies raised in different species (e.g., rabbit anti-CPEB4 with mouse anti-EMT markers)

  • Validate antibody performance individually before combining

  • Use spectral unmixing in cases of fluorophore emission overlap

• Multi-parameter flow cytometry:

  • CPEB4 antibodies validated for flow cytometry can be combined with cell cycle markers

  • Optimize fixation and permeabilization conditions for intracellular CPEB4 detection

  • Use appropriate compensation controls to account for spectral overlap

• Sequential immunostaining approaches:

  • For tissues with limited availability, consider sequential staining protocols

  • Document and digitally analyze each staining round before antibody stripping

  • Use image registration algorithms to align multiple staining rounds

• Multiplexed protein detection platforms:

  • Adapt CPEB4 antibodies for use in technologies like imaging mass cytometry or multiplexed ion beam imaging

  • Validate antibody performance in these specialized applications

  • Combine with key markers of interest (e.g., ZEB1, E-cadherin)

What considerations are important when analyzing contradictory CPEB4 expression data across different studies?

When reconciling conflicting CPEB4 data:

• Antibody-related variables:

  • Different antibodies may recognize distinct epitopes, resulting in discrepant findings

  • Validate antibody specificity using knockout controls as demonstrated in the literature

  • Check whether polyclonal vs. monoclonal antibodies were used

• Methodological differences:

  • Detection methods vary in sensitivity (Western blot vs. IHC vs. ELISA)

  • Scoring systems differ between studies (e.g., different IRS calculation methods)

  • Sample preparation protocols impact antigen availability and detection

• Biological context variations:

  • Cell/tissue type differences affect CPEB4 expression and function

  • Disease stage influences expression patterns (early vs. advanced cancer)

  • Heterogeneity within samples may not be captured by some techniques

• Data interpretation approaches:

  • Continuous vs. categorical analysis of expression data

  • Threshold setting for "high" vs. "low" expression varies between studies

  • Statistical methods differ in their sensitivity to detect associations

How can researchers distinguish CPEB4 from other CPEB family members in experimental systems?

Distinguishing CPEB4 from other family members requires:

• Antibody selection considerations:

  • Choose antibodies raised against unique regions of CPEB4 not conserved among family members

  • Validate specificity using cells with CPEB4 knockout but expression of other family members

  • Perform Western blot analysis to confirm the antibody detects a single band at the appropriate size (approximately 80-90 kDa)

• Expression pattern analysis:

  • CPEB4, unlike CPEB1 and CPEB3, does not play a significant role in synaptic plasticity, learning, and memory

  • Different family members show distinct tissue expression patterns that can aid identification

  • Consider the cellular localization pattern as a distinguishing feature

• Functional validation approaches:

  • Implement gene-specific knockdown using targeted siRNAs/shRNAs

  • Perform rescue experiments with CPEB4-specific constructs

  • Assess functional readouts known to be unique to CPEB4 (e.g., specific aspects of EMT regulation)

• RNA-binding specificity:

  • CPEB4 binds to CPE elements with the consensus sequence 5'-UUUUUAU-3'

  • Different CPEB family members may show subtle differences in binding preferences

  • RNA-immunoprecipitation can confirm target specificity

What are the emerging research directions for CPEB4 antibody applications in neurodegenerative disease studies?

Emerging applications in neurodegenerative research include:

• Alzheimer's disease connections:

  • Research suggests CPEB4 may regulate stress responses relevant to neurodegeneration

  • Antibodies are being used to track CPEB4 expression changes in disease progression

  • Particularly useful in hippocampal studies, as demonstrated by immunohistochemical analysis of mouse hippocampus tissue

• Stress response mechanisms:

  • CPEB4's role in unfolded protein response (UPR) makes it relevant to neurodegenerative conditions

  • Antibodies help monitor CPEB4-mediated translation regulation under stress conditions

  • Important for understanding protein misfolding diseases

• Differential tissue expression profiling:

  • Mapping CPEB4 expression across brain regions in health and disease

  • Correlating expression with disease severity and progression

  • Using multiplexed approaches to co-localize with disease-specific markers

• Therapeutic target validation:

  • Antibodies as tools to validate CPEB4 as a potential therapeutic target

  • Monitoring effects of experimental therapies on CPEB4 expression and activity

  • Developing imaging biomarkers based on CPEB4 expression patterns

What controls are essential when performing CPEB4 antibody-based experiments?

Essential controls include:

• Positive and negative cell/tissue controls:

  • Positive controls: SGC7901 cells (high CPEB4 expression)

  • Negative/low expression controls: AGS cells, GES-1 cells

  • Knockout controls: CPEB4 knockout A549 cell lysates

• Antibody controls:

  • Primary antibody omission control to assess background staining

  • Isotype control to evaluate non-specific binding

  • Secondary antibody-only control to check for background

• Technical validation controls:

  • Loading controls for Western blot (GAPDH is commonly used)

  • Internal reference markers for IHC and IF

  • Multiple antibody dilutions to establish optimal working concentration

• Biological validation approaches:

  • Confirmation with multiple antibodies targeting different epitopes

  • Correlation of protein detection with mRNA expression

  • Complementary detection methods (e.g., Western blot confirmation of IHC findings)

How can researchers quantitatively assess CPEB4 expression in complex tissue samples?

Quantitative assessment of CPEB4 in tissues can be accomplished through:

• Immunohistochemistry quantification:

  • Implement the immunoreactive score (IRS) system combining intensity and percentage

  • Staining intensity: 0=negative, 1=weak, 2=moderate, 3=strong

  • Percentage of positive cells: 0=0%–5%, 1=6%–25%, 2=26%–50%, 3=>50%

  • Calculate IRS by summing these scores (range 0-6)

  • Samples with IRS≥3 are considered positive

• Digital image analysis approaches:

  • Use computational pathology tools for objective assessment

  • Implement machine learning algorithms for pattern recognition

  • Quantify cell-by-cell expression in heterogeneous samples

• Protein extraction and quantification:

  • Western blot with densitometry analysis normalized to loading controls

  • ELISA-based quantification for high-throughput assessment

  • Consideration of tissue heterogeneity through microdissection techniques

• Multi-parameter correlation analysis:

  • Correlate CPEB4 levels with clinical parameters and outcomes

  • Integrate with other molecular markers for comprehensive profiling

  • Consider both nuclear and cytoplasmic staining patterns in analysis

What are the recommended approaches for validating novel findings related to CPEB4 function?

For robust validation of CPEB4-related discoveries:

• Multi-level confirmation strategy:

  • Verify findings at mRNA and protein levels

  • Use multiple detection techniques (Western blot, IHC, immunofluorescence)

  • Implement both in vitro and in vivo experimental systems

• Genetic manipulation approaches:

  • Apply both knockdown and overexpression methodologies

  • Use multiple targeting sequences for knockdown studies

  • Perform rescue experiments to confirm specificity

• Mechanistic investigations:

  • Identify direct binding partners and downstream targets

  • Confirm functional relationships through co-immunoprecipitation

  • Establish causality through sequential manipulation experiments

• Translational validation:

  • Correlate experimental findings with human patient samples

  • Assess relationships with clinical parameters and outcomes

  • Validate across multiple patient cohorts when possible

• Cross-species verification:

  • Test conservation of findings across model organisms

  • Consider species-specific differences in CPEB4 function

  • Validate antibody cross-reactivity when extending to different species